Eyenovia Inc (EYEN)EYEN

Eyenovia Inc.: A Comprehensive Overview

Company Profile:

Detailed History and Background:

Eyenovia Inc. is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in New York City. The company focuses on developing and commercializing micro-dosing technology for the treatment of ophthalmic diseases. Eyenovia began trading on the Nasdaq in 2022 under the ticker symbol EYEN.

Core Business Areas:

Eyenovia's core business areas are:

• Microdosing Technology: The company's proprietary microdosing technology utilizes small, precise doses of medication delivered to the eye using a proprietary applicator. This technology aims to improve drug efficacy and safety while reducing side effects.
• Ophthalmic Disease Therapy: Eyenovia focuses on developing treatments for various ophthalmic diseases, including presbyopia, glaucoma, and dry eye disease.

Leadership Team and Corporate Structure:

• Dr. Michael D. Rowe: President and CEO
• Dr. Peter J. O'Brien: Chief Medical Officer
• Ms. Donna S. LaVoie: Chief Financial Officer
• Mr. Mark A. Koch: Chief Business Officer
• Dr. David A. Drutz: Executive Vice President, Research and Development

For more information on the leadership team and board of directors, please visit https://www.eyenovia.com/management-team/.

Top Products and Market Share:

Top Products and Offerings:

• Micro-Dose Carbachol: A micro-dosed formulation of carbachol being developed for the treatment of presbyopia, a condition that affects near vision.
• Micro-Dose Pilocarpine: A micro-dosed formulation of pilocarpine being developed for the treatment of open-angle glaucoma and ocular hypertension.
• EY-101: A novel sustained-release microparticle formulation of atropine for the treatment of myopia.

Market Share:

Eyenovia's products are still under development and not yet commercially available. Therefore, they do not currently have a market share.

Product Performance and Market Reception:

Data on product performance and market reception are not yet available as the products are not yet commercially available.

Total Addressable Market:

The global ophthalmic pharmaceuticals market was valued at approximately $27.5 billion in 2022 and is expected to grow at a CAGR of 5.2% to reach $39.2 billion by 2030. Eyenovia's target markets are significant segments within this larger market.

• Presbyopia: This condition affects over 1.8 billion people globally, representing a significant market opportunity.
• Glaucoma: This chronic eye disease affects over 70 million people worldwide, with over 12 million cases in the US.
• Dry Eye Disease: This prevalent condition affects over 30 million Americans and is expected to grow with the aging population.

Financial Performance:

Eyenovia is a clinical-stage company and has not yet generated significant revenue or net income.

• Revenue: $6.5 million in 2022, primarily from collaborations and licensing agreements.
• Net Income: -$15.8 million in 2022, due to ongoing research and development expenses.
• EPS: -$1.26 in 2022.
• Cash Flow: Eyenovia's cash flow is primarily driven by financing activities and is negative due to ongoing R&D expenses.
• Balance Sheet: The company has a relatively healthy balance sheet with $99.5 million in cash and equivalents as of September 30, 2023.

For more detailed financial information, please refer to Eyenovia's latest financial reports available on their investor relations website: https://www.eyenovia.com/investors/.

Dividends and Shareholder Returns:

Dividend History:

Eyenovia is a clinical-stage company and does not currently pay dividends to shareholders.

Shareholder Returns:

Eyenovia's share price has been volatile since its IPO in 2022. The stock has experienced significant fluctuations due to various factors, including clinical trial results and market sentiment.

Growth Trajectory:

Historical Growth:

Eyenovia has experienced rapid growth in its early years, primarily driven by R&D investments and licensing agreements.

Future Growth:

Eyenovia's future growth will depend on the success of its clinical trials and commercialization efforts for its lead product candidates. The company has several ongoing clinical trials for its micro-dosed carbachol in presbyopia and micro-dosed pilocarpine in glaucoma.

Recent Initiatives:

• In July 2023, Eyenovia announced positive topline results from a Phase 2b clinical trial for Micro-Dose Carbachol for the treatment of presbyopia.
• The company is also actively seeking strategic partnerships to support the commercialization of its products.